Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

136.25 +2.32 (+1.73%)
Streaming Delayed Price Updated: 11:12 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
Via Benzinga
AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer
Via Benzinga
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
Via Benzinga
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline
Via Benzinga
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
Via Benzinga
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
Via Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting
Via Benzinga
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
Via Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Via Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
Via Benzinga
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Via Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
Via Benzinga
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
Via Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
Via Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine
Via Benzinga
AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
Via Benzinga
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings
Via Benzinga
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Via Benzinga
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
Via Benzinga
AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial
AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. 
Via Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
Via Benzinga
How To Invest In UK Market Turmoil
With investors speculating about what steps the central bank might take, it’s clear that the UK’s turbulence is far from over. So, let’s take a look at the market winners and losers that are likely to... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.